Reduction of low-density lipoprotein cholesterol (LDL-C) is central to the management of cardiovascular risk associated with dyslipidaemia. Yet, at best, this strategy is only capable of a reduction of about 50% in ischaemic vascular disease. Therefore, there is still a need for interventive strategies to improve the situation. Triglyceride lowering and high-density lipoprotein cholesterol (HDL-C) elevation feature prominently in this context, a viewpoint increasingly adopted by international treatment guidelines. This article reviews current thinking on the subject and offers additional treatment strategies for the dyslipidaemic patient.
LaRosa JC , He J., Vupputuri S.Effects of statins on risk of coronary disease. A meta-analysis of randomised, controlled studies. JAMA1999; 282:2340-6.
2.
Expert panel on detection, evaluation and treatment of high blood cholesterol in adults.Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. J Am Med Assoc2001;285:2486-97.
3.
De backer G., Ambrosioni E., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J2003;24:1601-10.
4.
Heart Protection StudyCollaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals . A randomised, placebo-controlled trial. Lancet2002;360:7-22.
5.
Franceschini G., Sirtori CR, Capurso A. et al. A-I Milano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest1980;66:892-900.
6.
Weisgraber KH , Rall SC, Bersot TP et al. Apolipoprotein A.- I. Milano.Detection of normal A-I in affected subjects and evidence for a cystine for arginine substitution in the variant A-I. J Biol Chem1983;258: 2508-13.
7.
Gualandri V. , Franceschini G., Sirtori CR et al. A-I Milano Apoprotein. Identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet1985;37:1083-97.
8.
Franceschini G., Sirtori CR, Bosisio E. et al. Relationship of the phenotypic expression of the A-I Milano apoprotein with plasma lipid and lipoprotein patterns. Atherosclerosis1985;58:159-74.
9.
Franceschini G., Calabresi L., Chiesa G. et al. Increased cholesterol efflux potential of sera from apo A-I Milano carriers and transgenic mice. Arterioscler Thromb Vasc Biol1999;19:1257-62.
10.
Ameli S., Hultgardh-Nilsson A., Cercek B. et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation1994;90:1935-41.
11.
Fruchart JC , Staels B., Duriez P.The role of fibric acids in atherosclerosis . Curr Atheroscler Rep2001;3:83-92.
12.
Frick MH, Elo O., Haapa K. et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle aged men with dyslipidaemia. N Engl J Med1987;317:1237-45.
13.
The BIP Study Group.Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation2000;102:21-7.
14.
Rubins HB, Robins SJ, Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med1999;341:410-18.
15.
Manninen V. , Elo O., Frick MH et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA1988;260:641-55.
16.
Yuan J., Tsai MY, Hunninghake DBChange in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis1994;110:1-11.
17.
Robins SJ, Collins D., Wittes JT et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomised controlled trial. JAMA2001;285:1585-91.
18.
McKenney JM , Proctor JD, Harris S., Chinchili VMA comparison of the efficacy and toxic effects of sustained versus immediate-release niacin in hypercholesterolemic patients . JAMA1994;271:672-7.
19.
The Coronary Drug Project Research Group.Clofibrate and niacin in coronary heart disease. JAMA1975;231:360-81.
20.
Canner PL, Berge K., Wenger NK et al. Fifteen year mortality in Coronary drug Project patients: long term benefit with niacin. J Am Coll Cardiol1986;8:1245-55.
21.
Brown BG, Zhoo X-Q., Chart A. et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary dis
22.
Bays HE, Dujovne CA, McGovern M. et al. Comparison of once daily niacin extended release/lovastatin with standard doses of atorvastatin and simvastatin (ADVOCATE). Am J Cardiol2003;91:667-72.
